Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.44 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.42 |
| ▸ | CPS1 | P31327 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | GPR183 | P32249 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16149875 | 0.86 | MEN1 (0.51) | POLBGPR119DYRK2GPR183HDAC4 | |
| SCHEMBL21877999 | 0.83 | ATR (0.47) | CPS1KDM1AGPR183PIK3CAMTOR | |
| SCHEMBL17390089 | 0.82 | FASN (0.53) | KDM1AGPR183 | |
| Hydrochloric Acid SCHEMBL21878141 | 0.82 | ATR (0.46) | DYRK2CPS1KDM1AGPR183PIK3CA | |
| Hydrochloric Acid SCHEMBL21878020 | 0.82 | ATR (0.46) | DYRK2CPS1KDM1AGPR183PIK3CA | |
| SCHEMBL17389646 | 0.80 | FASN (0.44) | CPS1KDM1AGPR183MTOR | |
| SCHEMBL17389586 | 0.79 | FASN (0.43) | CPS1KDM1AGPR183MTOR | |
| SCHEMBL16150781 | 0.77 | GHSR (0.49) | CPS1KDM1APIK3CAMTOR | |
| SCHEMBL16150783 | 0.77 | GHSR (0.49) | CPS1KDM1APIK3CAMTOR | |
| SCHEMBL2846468 | 0.76 | KDM4E (0.55) | POLBCPS1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267805-B2 | Solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl) piperazine-1-yl)(1-hydroxycyclopropyl)methanone | FORMA THERAPEUTICS, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| CN-113382633-A | Solid forms of (4- (2-fluoro-4- (1-methyl-1H-benzo [ d ] imidazol-5-yl) benzoyl) piperazin-1-yl) (1-hydroxycyclopropyl) methanone | 福马治疗股份有限公司 | 2021-09-10 | — | — | CN | disclosed |
| EP-3873214-A1 | SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[D]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE | Forma Therapeutics, Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20200392114-A1 | SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZINE-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE | FORMA THERAPEUTICS, INC. | 2020-12-17 | — | — | US | disclosed |
| US-10793554-B2 | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone | FORMA THERAPEUTICS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20200131155-A1 | SOLID FORMS OF 4-(2-FLUORO-4-(1-METHYL-1H-BENZO[d]IMIDAZOL-5-YL)BENZOYL)PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE | FORMA THERAPEUTICS, INC. | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392114-A1 | SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZINE-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE | HTR2C, AURKAIP1, COX4I1 | POLB 681/4885GPR119 4677/4885DYRK2 3763/4885 |
| US-10793554-B2 | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone | SSBP1, AURKAIP1, COX4I1 | POLB 477/4885GPR119 4715/4885DYRK2 4018/4885 |
| US-11267805-B2 | Solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl) piperazine-1-yl)(1-hydroxycyclopropyl)methanone | HTR2C, AURKAIP1, COX4I1 | POLB 681/4885GPR119 4677/4885DYRK2 3763/4885 |
| US-20200131155-A1 | SOLID FORMS OF 4-(2-FLUORO-4-(1-METHYL-1H-BENZO[d]IMIDAZOL-5-YL)BENZOYL)PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE | SSBP1, AURKAIP1, MFAP1 | POLB 536/4885GPR119 4658/4885DYRK2 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.